Contacts

NGR-hTNF

The broad clinical development programme of NGR-hTNF includes Phase II trials in seven different types of solid tumours, as monotherapy in colorectal cancer, hepatocellular carcinoma and mesothelioma, or in combination with standard chemotherapeutic agents in small-cell lung cancer, non-small cell lung cancer, ovarian cancer and soft-tissue sarcoma.
Furthermore, NGR-hTNF was investigated in a Phase III trial in mesothelioma patients.

Currently, the randomised Phase II trial in mesothelioma as first-line maintenance therapy is ongoing.

MolMed S.p.A. Via Olgettina, 58 - 20132 Milano, Italy | Phone +39 0221277.1 - Fax +39 02 21277.325 | info@molmed.com - www.molmed.com
Share capital € 20,312,682.30 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159